Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders.
The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.
The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment
Pioneer in uniting imaging technology with radiotherapy to explore potential of MRI to refine tumor targeting.
Uppsala University Hospital (UUH) and Elekta today announced that they have signed an agreement to jointly work at the forefront of imaging in cancer care research.
Elekta and Royal Philips announced today that The Institute of Cancer Research, London, will join the Elekta MR Linac Research Consortium, a group with a mission to develop an integrated magnetic resonance imaging (MRI) guided radiation therapy system.
Largest medical center in the Netherlands upgrades with several Elekta Versa HD linear accelerators
Study: For treating multiple metastases, Elekta’s Gamma Knife offers dramatically lower radiation dose to normal brain than other systems
Multi-institutional radiotherapy planning study compared Leksell Gamma Knife Perfexion with three advanced linear-accelerator based stereotactic radiosurgery systems.